CVR 27913547Private limited company (ApS)Anden finansiel formidling undtagen forsikring og pensionsforsikring, i.a.n. (649900)FredensborgFounded 17 Jun 2004
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about AFLEX ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexResult
-12.8K
DKK, annual report 2020
Equity
90.5K
DKK, annual report 2020
VELIN-PHARMA A/SCVR 33026013, 100% of capital and votes, until 10 Jun 2021
Flemming Velinuntil 10 Jun 2021
No current owner is registered.
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR 33026013100% of capital and votes17 Jun 2004 to 10 Jun 2021
Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report a calibrated decision model reading the auditor's text, not registered by the company. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
17 Jun 2004 to 13 Nov 2026.
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Operating profit | -12 | -14 | -15 | -15 | -19 |
| Result for the year | -7 | -9 | -10 | -10 | -13 |
| Equity | 132 | 123 | 114 | 103 | 90 |
| Total assets | 166 | 170 | 174 | 178 | 183 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
DKK thousands. Annual reports via XBRL.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions.
Annual report 2020
1 Jun 2019 to 31 May 2020, published 2 Nov 2020
Annual report 2019
1 Jun 2018 to 31 May 2019, published 30 Oct 2019
Annual report 2018
1 Jun 2017 to 31 May 2018, published 30 Oct 2018
Annual report 2017
1 Jun 2016 to 31 May 2017, published 31 Oct 2017
Annual report 2016
1 Jun 2015 to 31 May 2016, published 28 Oct 2016
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For AFLEX ApS, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
From CVR, read 13 Nov 2026. Text such as the signing rule and purpose is shown as registered.
From CVR, read 13 Nov 2026. A change is counted each time the registry records a new value, so a corrected address or an audit firm under a new entity counts too.
6 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Virksomheden er opløst ved erklæring efter selskabslovens § 216, jf. lov om erhvervsdrivende virksomheder § 20
Bestyrelse:
Fratrådte:
Niels Ebbe Valdal, (formand), den 10.06.2021, Flemming Velin, den 10.06.2021, Majken Velin, den 10.06.2021.
Direktion:
Fratrådte:
Flemming Velin, den 10.06.2021.
Revision:
Fratrådte:
GLB REVISION, STATSAUTORISEREDE REVISORER A/S, den 10.06.2021.
Vedtægter ændret:
30.07.2010.
Nyt navn:
AFLEX ApS.
Ved kommunalreformen den 1. januar 2007 er hjemstedskommunen ændret.
Stiftelsesdato:
17.06.2004.
Seneste vedtægtsdato:
17.06.2004.
Kapital:
kr. 125.000,00.
Indbetalingsmåde:
kontant kr. 125.000,00 til kurs 104,00.
Stifter:
CVR-NR. 33026013 VELIN-PHARMA A/S, Kongevejen 66, 3480 Fredensborg, den 17.06.2004.
Bestyrelse:
Advokat Niels Ebbe Valdal (formand), den 17.06.2004, Direktør Flemming Velin, den 17.06.2004, Fru Majken Velin, den 17.06.2004.
Direktion:
Direktør Flemming Velin, den 17.06.2004.
Selskabet tegnes af direktøren alene eller af to medlemmer af bestyrelsen i forening.
Revision:
CVR-NR. 66001113 IVER H. IVERSEN STATSAUTORISEREDE REVISORER ApS, Mynstersvej 3, 3. tv., 1827 Frederiksberg C, den 17.06.2004.
Første regnskabsår:
17.06.2004 - 31.05.2005.
Regnskabsår:
01.06 - 31.05.
1 registered in CVR.
P-number 1010631471Kongevejen 66, 3480 Fredensborg